Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

purified extract of Cannabidiol, or CBD)
  • FDA orphan drug designation granted by FDA for Epidiolex in Dravet syndrome
  • Seven physician-led INDs granted by FDA to treat 125 pediatric epilepsy patients in the U.S. with Epidiolex
  • Epidiolex pediatric epilepsy clinical trials in planning for 2014
  • Additional epilepsy pipeline candidate, GWP42006 (Cannabidivarin or CBDV), commenced Phase 1 trial in September 2013
  • Significant clinical activity for GW's other cannabinoid pipeline product candidates, including:
  • Positive preliminary data reported from a Phase 2a exploratory clinical trial of the novel cannabinoid medicine GWP42004 in type-2 diabetes with a Phase 2 dose ranging trial expected to commence in early 2014
  • Phase 2 trial of GWP42003 for the treatment of ulcerative colitis on-going with data expected in the first half of 2014
  • Phase 2 trial of GWP42003 for the treatment of schizophrenia expected to commence in the first half of 2014
  • Phase 1b/2a trial of THC:CBD for the treatment of glioma commenced in November 2013
  • Financial Highlights

  • Total revenue for 2013 of £27.3m ($44.2m) compared to £33.1m in 2012. 2012 revenues included a £9.8m milestone receipt compared to £0.3m milestone income in 2013.
  • Net loss after tax for 2013 of £4.5m ($7.4m) compared to a profit after tax of £2.5m in 2012, which primarily reflected the impact of the £9.8m milestone payment received last year.
  • Cash and cash equivalents at 30 September 2013 of £38.1m ($61.6m) compared to £29.3m as at 30 September 2012.
  • "This was a transformative year for GW with the successful completion of an IPO on NASDAQ, progress with two Phase 3 programs for Sativex in the United States, and the emergence of a new exciting orphan development program in childhood epilepsy," stated Justin Gover, GW's Chief Executive Officer. "We believe that th
    '/>"/>

    SOURCE GW Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
    10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    11. Avanir Pharmaceuticals To Present at Three Conferences In May
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
    (Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
    (Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ... ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, Schedule ... ) today, and provides an update for shareholders detailing why ... is requested. Dear Shareholders, As we ...
    Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
    ... MASI ), the inventor of Pulse CO-Oximetry(TM) ... that three new independent studies demonstrating the clinical accuracy ... continuous measure of patient fluid status and responsiveness were ... (ESA) Annual Congress in Milan, Italy. , ...
    ... in End of Phase 2a Meeting , , ... VIAP ), a biotechnology company focused on the development ... announced today that an end of Phase 2a meeting for ... the U.S. Food and Drug Administration (FDA). The Company ...
    Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
    (Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
    (Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
    (Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
    (Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
    Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
    ... Who: The American Society for Radiation Oncology (ASTRO) the world,s ... 10,000 members who use radiation to treat cancer and other ... ASTRO,s 53rd Annual Meeting: "Patient-focused, High-quality, Multidisciplinary Care." ... a.m. - 4:30 p.m. Note: Press room days have changed. ...
    ... (HealthDay News) -- Older, heavier women tend to have fewer ... study suggests. The study included 52 women who experienced ... The women,s body fat percentage, waist circumference and ... skin monitor and electronic diary were used to track their ...
    ... News) --,Hospitalized children who carry a dangerous type of ... still at high risk for developing full-blown infections, a ... aureus (MRSA) -- is linked to more than 18,600 ... Hopkins Children,s Center researchers examined the medical records of ...
    ... defibrillators, simpler may be safer, even though more complex machines ... a new study from a team that included University of ... reviewed more than 100,000 records of cardiac patients. They found ... with devices that require electrical leads to be attached to ...
    ... [EMBARGOED FOR AUG. 31, 2011, ARLINGTON, Va.] Immunizations, ... to protect children from life-threatening pneumonia, according to new ... the Infectious Diseases Society of America (IDSA)., The guidelines, ... pneumonia (CAP) in infants and children, place preventing bacterial ...
    ... , TUESDAY, Aug. 30 (HealthDay News) -- Changes in diet ... researchers say. Their findings, published online Aug. 30 in ... virus populations in the gut, how they differ from person ... "Our bodies are like coral reefs, inhabited by ...
    Cached Medicine News:Health News:Being Heavier May Mean Fewer Hot Flashes for Women Over 60 2Health News:Kids Carrying MRSA Germ Prone to Serious Infection: Study 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 2Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 3Health News:IDSA/PIDS announce guidelines for treating pneumonia in children 4
    ... new system to help you meet the ... system's one-piece design creates a broad area ... radiographic assessment. The slotted superior and inferior ... column and are flared outward for greater ...
    ... With 36 joules delivered energy, the Atlas+ HF ... patient safety, programming flexibility, comfort, and quality of ... most powerful ICD offering cardiac resynchronization therapy (CRT), ... 81 gram and 40 cc physiologic-shaped can. In ...
    ... Intramedullary fixation has greatly ... tibial fractures. The Biomet Low ... indicated in the treatment of ... metastatic disease with pathologic or ...
    ... The Elite™ Premium Shoulder Instrument ... flexibility in arthroscopic and mini-open ... cuff and Bankart repair. Smith ... been designed to facilitate an ...
    Medicine Products: